Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer

Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yaohui, Bi, Dexi, Xie, Ruting, Li, Man, Guo, Jing, Liu, Hu, Guo, Xianling, Fang, Juemin, Ding, Tingting, Zhu, Huiyuan, Cao, Yuan, Xing, Meichun, Zheng, Jiayi, Xu, Qing, Xu, Qian, Wei, Qing, Qin, Huanlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602417/
https://www.ncbi.nlm.nih.gov/pubmed/34795206
http://dx.doi.org/10.1038/s41392-021-00795-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602417/
https://www.ncbi.nlm.nih.gov/pubmed/34795206
http://dx.doi.org/10.1038/s41392-021-00795-x

Ejemplares similares